Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccine response against SARS-CoV-2 in patients with primary Sjögren’s syndrome
2021-001414-10Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Protective antibody titers difference at day 28 after second vaccination. Started Mar 2021; status: completed.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001414-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001414-10.